Wednesday, June 13, 2012 11:13:09 PM
$$$$$==Ultimate DD SS included RXPC-UPDATED===$$$$$
Just a start to DD, lots more in the works.. I am still waiting on conformation.
California Corporation "Active"
http://kepler.sos.ca.gov/cbs.aspx
Our Onko-Sure® in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). Onko-Sure® is a simple, non-invasive blood test used for the detection and/or monitoring of 15 different types of cancers.
Onko-Sure FDA Approval (which means tested and works)
http://www.biomedreports.com/2010040835254/radients-fda-approved-diagnostic-test-detects-cancer-sooner.html
RPC Videos:
Doctor http://www.youtube.com/watch?v=J27Id9Bl5Pk
Patients http://www.youtube.com/watch?v=A3YBSg2OInQ
CEO http://www.youtube.com/watch?v=NuInWZUUdD4&feature=related
More information is available at http://www.radient-pharma.com
Pay close attention to the details of the 8K ... almost all companies have debt, but here you have a company with a FDA approved product that was trading on AMEX, that is restructuring without going into BK, which based on the information seems to be in the best interest of everyone (including note holders), now the company stated it needed funds for fillings for the SEC and restructuring so I believe the recent sales were necessary to keep the company above water, notice below management is working stabilizing the company (I am expecting the selling to halt and PPS to move back up based on the 8K below).
- at this stage i expect one of two thing: BUY OUT or Management will seek a positive net income..
Information from (8K 05/21/2012)
http://ih.advfn.com/p.php?pid=nmona&article=52494292
As previously disclosed in our recent filings, we have been experiencing severe working capital shortages. In addition, substantially all of the holders of approximately $14.0 million of our notes and redeemable preferred shares (the “2011 Noteholders”) had previously declared defaults and demanded repayment of these obligations, which we were unable to pay.
On May 17, 2012, we completed an Agreement with the 2011 Noteholders, severally and not jointly, for the exercise of an aggregate of $150,000 worth of our Series A Common Stock Purchase Warrants at an exercise price of $0.02619 per share
As a condition to the exercise of the Warrants, we agreed that following the date of the Agreement and through and including 5:00 p.m. (EDT) on August 31, 2012, we will not file in any U.S. Bankruptcy Court a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code or seek to liquidate under Chapter 7 of such Code. Additionally, each of the 2011 Noteholders, severally and not jointly, agreed to forebear (NOT TO CALL NOTES/SELL "KEY")from exercising any of their rights and remedies,
Information from (8K 04/30/2012)
As a result of our working capital deficiencies, we have recently laid off a substantial portion of our work force and are currently operating on a minimal basis with only 2 employees and three former employee consultants. The current focus of our operations is to ensure that our existing Onko-Sure® customers and any future customers are able to place orders and receive kits on a timely basis.
We have an Onko-Sure® production continuity arrangement in place with one vendor.
At the current time, the Company believes that it does not require any additional staff to perform this limited manufacturing, quality control and selling process
Share Structure
Shares Outstanding 900Million a/o June 13, 2012 Projected, will call TA.
Float: Pending
Authorized Shares 5Billion a/o Jun 13, 2012
Corporate Stock Transfer, Inc.
Transfer Agent
3200 Cherry Creek Drive South
Suite 430
Denver, CO, 80209
303-282-4800
52 Week Range .33 to .0001
About Onko-Sure®
When you know, you can act.
Onko-Sure® is a simple, non-invasive and FDA cleared in vitro diagnostic (IVD) blood biomarker test used both for monitoring colorectal cancer (CRC) during treatment and afterwards for recurrence monitoring. It helps CRC patients and their healthcare team of physicians plan a pro-active treatment program and follow-up plan for patients after a CRC diagnosis.
In medical terms, it measures Fibrin/Fibrinogen Degradation Products (FDP) in the blood serum. If these elements are found to be present, the physician can use this information to better plan and focus the post-diagnosis treatment program. Identifying colorectal cancer recurrences earlier and treating it properly can lead to a better survival rate and quality of life.1
Note: Onko-Sure® is available in the United States for monitoring of CRC treatment and recurrence.
Onko-Sure® offers some specific advantages over other approaches:
¦Simple, non-invasive blood test
¦Clinically proven in 12 published studies for monitoring of colorectal cancer treatment and recurrence
¦Floats freely in blood (which makes it more effective even in lower concentrations of the marker)
Here are some of the details—and don’t worry if this is a bit over your head. Your physician can help explain:
For the last 25 years, Carcinoembryonic Antigen (CEA) (sensitivity of 38-69%) and CA 19-9 (sensitivity of 23-65%) have been available blood biomarkers for colorectal cancer (CRC) treatment and follow-up monitoring. However, similar to any other biomarker, they have their own limitations.1 DR-70® (sensitivity of 54-87%) is the most recent biomarker cleared by the US FDA for the monitoring of colorectal cancer treatment and recurrence. It has been shown by two recent clinical studies performed in the UK and US in 2010 that combining CEA and DR-70® improves the test sensitivity to 55% higher than that of CEA alone.
How Onko-Sure® Works
The production of Fibrin and Fibrinogen Degradation Products (FDP) is restricted in healthy individuals by normal cells. However, cancer cells release proteolytic enzymes such as plasmin and thrombin as they grow and metastasize. They also redirect the coagulation cascade which leads to overproduction of FDP in the process of carcinogenesis.2-4
FDP level measurement is routinely performed for the detection of coagolopathies. However, the current assays for FDP measurement usually detect only one out of the many FDP components (D-dimer).5 There have been many publications studying the D-dimer level measurement in different malignancies including CRC6-9; however, it is not approved for detecting or monitoring malignancies.
Onko-Sure® is the first blood test available for the monitoring of colorectal cancer treatment and recurrence based on FDP measurement. It is an ELISA-based test that uses DR-70® polyclonal antibody against the full array of FDP. Onko-Sure® detects all of the breakdown products of Fibrin and Fibrinogen, including a unique cancer-related breakdown product, Initial Plasmin Degradation Product (IPDP).10
Clinical data supports the medical utilization of Onko-Sure® for the monitoring of colorectal cancer. In these seven clinical studies, Onko-Sure® was used to measure DR-70 levels in about 6,000 patients and the results positively correlated with the progression of CRC.1,10-14 Furthermore, as reported by six other studies, the D-dimer level was also linked to CRC progression in about 500 patients.2,6-9
Comparison of Onko-Sure® with CEA
CEA, an adhesion molecule, is firmly attached to cancer cells.15 Therefore, it is less abundant in blood and more difficult to be measured. However, DR-70 antigen is freely diffusible in blood and therefore easy to measure even in low concentrations in lower stages of the cancer. Approximately 35% of all CRC patients experience recurrence.16 Of those, half of them have low CEA values not detectable by CEA test.17-19 For this reason, Onko-Sure® has advantages over CEA in detecting lower levels of this biomarker leading to an early detection of recurrence.
Figure 1. Comparison of Onko-Sure® with CEA. A large number of CRC patients have low CEA values (Concordance with Clinical Findings (%)
The Concentration of Biomarker (ng/ml)
(CEA = Carcinoembryonic Antigen)
CEA has approximately a 20% chance of false positive in smokers20 while Onko-Sure® measurements are not affected by smoking.
In general, it has been found that a combination of several biomarkers provides more accurate information for CRC monitoring. Therefore, it is recommended that both CEA and Onko-Sure® are used in combination for the monitoring of post-surgery CRC recurrence21.
More clinical studies are ongoing to verify the beneficial effect of CEA combination with Onko-Sure®. Furthermore, Onko-Sure® should be used in conjunction with other clinical modalities considered to be the standard of care for CRC disease progression monitoring.
Summary
Onko-Sure® is a simple, non-invasive, patent-pending blood test used both for monitoring colorectal cancer (CRC) during treatment and for post-treatment CRC recurrence. It is an ELISA-based assay that measures the accumulation of Fibrin/Fibrinogen Degradation Products (FDP) in the serum using a polyclonal antibody (DR-70) as a blood biomarker.
For the last 25 years, CEA has been the main routine biomarker for CRC monitoring. DR-70 is the most recent biomarker cleared by the US FDA for the monitoring of colorectal cancer treatment and recurrence. It is recommended to use these two tests in combination to increase the test sensitivity for the monitoring of CRC treatment and recurrence (supported by 2 clinical studies in 2011).
The information on this website is intended for healthcare professionals practicing in the US. If you or a loved one want to know more about Onko-Sure, we encourage you to discuss it with your physician or other healthcare professional.
http://www.onko-sure.com/about-onko-sure/
http://investorshub.advfn.com/boards/addPersonMrk.asp?user=205909 (CLICK IF YOU LIKE STREAMER)
Just a start to DD, lots more in the works.. I am still waiting on conformation.
California Corporation "Active"
http://kepler.sos.ca.gov/cbs.aspx
Our Onko-Sure® in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect solid tumor cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). Onko-Sure® is a simple, non-invasive blood test used for the detection and/or monitoring of 15 different types of cancers.
Onko-Sure FDA Approval (which means tested and works)
http://www.biomedreports.com/2010040835254/radients-fda-approved-diagnostic-test-detects-cancer-sooner.html
RPC Videos:
Doctor http://www.youtube.com/watch?v=J27Id9Bl5Pk
Patients http://www.youtube.com/watch?v=A3YBSg2OInQ
CEO http://www.youtube.com/watch?v=NuInWZUUdD4&feature=related
More information is available at http://www.radient-pharma.com
- at this stage i expect one of two thing: BUY OUT or Management will seek a positive net income..
http://ih.advfn.com/p.php?pid=nmona&article=52494292
As previously disclosed in our recent filings, we have been experiencing severe working capital shortages. In addition, substantially all of the holders of approximately $14.0 million of our notes and redeemable preferred shares (the “2011 Noteholders”) had previously declared defaults and demanded repayment of these obligations, which we were unable to pay.
On May 17, 2012, we completed an Agreement with the 2011 Noteholders, severally and not jointly, for the exercise of an aggregate of $150,000 worth of our Series A Common Stock Purchase Warrants at an exercise price of $0.02619 per share
As a condition to the exercise of the Warrants, we agreed that following the date of the Agreement and through and including 5:00 p.m. (EDT) on August 31, 2012, we will not file in any U.S. Bankruptcy Court a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code or seek to liquidate under Chapter 7 of such Code. Additionally, each of the 2011 Noteholders, severally and not jointly, agreed to forebear (NOT TO CALL NOTES/SELL "KEY")from exercising any of their rights and remedies,
As a result of our working capital deficiencies, we have recently laid off a substantial portion of our work force and are currently operating on a minimal basis with only 2 employees and three former employee consultants. The current focus of our operations is to ensure that our existing Onko-Sure® customers and any future customers are able to place orders and receive kits on a timely basis.
We have an Onko-Sure® production continuity arrangement in place with one vendor.
At the current time, the Company believes that it does not require any additional staff to perform this limited manufacturing, quality control and selling process
Share Structure
Shares Outstanding 900Million a/o June 13, 2012 Projected, will call TA.
Float: Pending
Authorized Shares 5Billion a/o Jun 13, 2012
Corporate Stock Transfer, Inc.
Transfer Agent
3200 Cherry Creek Drive South
Suite 430
Denver, CO, 80209
303-282-4800
52 Week Range .33 to .0001
About Onko-Sure®
When you know, you can act.
Onko-Sure® is a simple, non-invasive and FDA cleared in vitro diagnostic (IVD) blood biomarker test used both for monitoring colorectal cancer (CRC) during treatment and afterwards for recurrence monitoring. It helps CRC patients and their healthcare team of physicians plan a pro-active treatment program and follow-up plan for patients after a CRC diagnosis.
In medical terms, it measures Fibrin/Fibrinogen Degradation Products (FDP) in the blood serum. If these elements are found to be present, the physician can use this information to better plan and focus the post-diagnosis treatment program. Identifying colorectal cancer recurrences earlier and treating it properly can lead to a better survival rate and quality of life.1
Note: Onko-Sure® is available in the United States for monitoring of CRC treatment and recurrence.
Onko-Sure® offers some specific advantages over other approaches:
¦Simple, non-invasive blood test
¦Clinically proven in 12 published studies for monitoring of colorectal cancer treatment and recurrence
¦Floats freely in blood (which makes it more effective even in lower concentrations of the marker)
Here are some of the details—and don’t worry if this is a bit over your head. Your physician can help explain:
For the last 25 years, Carcinoembryonic Antigen (CEA) (sensitivity of 38-69%) and CA 19-9 (sensitivity of 23-65%) have been available blood biomarkers for colorectal cancer (CRC) treatment and follow-up monitoring. However, similar to any other biomarker, they have their own limitations.1 DR-70® (sensitivity of 54-87%) is the most recent biomarker cleared by the US FDA for the monitoring of colorectal cancer treatment and recurrence. It has been shown by two recent clinical studies performed in the UK and US in 2010 that combining CEA and DR-70® improves the test sensitivity to 55% higher than that of CEA alone.
How Onko-Sure® Works
The production of Fibrin and Fibrinogen Degradation Products (FDP) is restricted in healthy individuals by normal cells. However, cancer cells release proteolytic enzymes such as plasmin and thrombin as they grow and metastasize. They also redirect the coagulation cascade which leads to overproduction of FDP in the process of carcinogenesis.2-4
FDP level measurement is routinely performed for the detection of coagolopathies. However, the current assays for FDP measurement usually detect only one out of the many FDP components (D-dimer).5 There have been many publications studying the D-dimer level measurement in different malignancies including CRC6-9; however, it is not approved for detecting or monitoring malignancies.
Onko-Sure® is the first blood test available for the monitoring of colorectal cancer treatment and recurrence based on FDP measurement. It is an ELISA-based test that uses DR-70® polyclonal antibody against the full array of FDP. Onko-Sure® detects all of the breakdown products of Fibrin and Fibrinogen, including a unique cancer-related breakdown product, Initial Plasmin Degradation Product (IPDP).10
Clinical data supports the medical utilization of Onko-Sure® for the monitoring of colorectal cancer. In these seven clinical studies, Onko-Sure® was used to measure DR-70 levels in about 6,000 patients and the results positively correlated with the progression of CRC.1,10-14 Furthermore, as reported by six other studies, the D-dimer level was also linked to CRC progression in about 500 patients.2,6-9
Comparison of Onko-Sure® with CEA
CEA, an adhesion molecule, is firmly attached to cancer cells.15 Therefore, it is less abundant in blood and more difficult to be measured. However, DR-70 antigen is freely diffusible in blood and therefore easy to measure even in low concentrations in lower stages of the cancer. Approximately 35% of all CRC patients experience recurrence.16 Of those, half of them have low CEA values not detectable by CEA test.17-19 For this reason, Onko-Sure® has advantages over CEA in detecting lower levels of this biomarker leading to an early detection of recurrence.
Figure 1. Comparison of Onko-Sure® with CEA. A large number of CRC patients have low CEA values (Concordance with Clinical Findings (%)
The Concentration of Biomarker (ng/ml)
(CEA = Carcinoembryonic Antigen)
CEA has approximately a 20% chance of false positive in smokers20 while Onko-Sure® measurements are not affected by smoking.
In general, it has been found that a combination of several biomarkers provides more accurate information for CRC monitoring. Therefore, it is recommended that both CEA and Onko-Sure® are used in combination for the monitoring of post-surgery CRC recurrence21.
More clinical studies are ongoing to verify the beneficial effect of CEA combination with Onko-Sure®. Furthermore, Onko-Sure® should be used in conjunction with other clinical modalities considered to be the standard of care for CRC disease progression monitoring.
Summary
Onko-Sure® is a simple, non-invasive, patent-pending blood test used both for monitoring colorectal cancer (CRC) during treatment and for post-treatment CRC recurrence. It is an ELISA-based assay that measures the accumulation of Fibrin/Fibrinogen Degradation Products (FDP) in the serum using a polyclonal antibody (DR-70) as a blood biomarker.
The information on this website is intended for healthcare professionals practicing in the US. If you or a loved one want to know more about Onko-Sure, we encourage you to discuss it with your physician or other healthcare professional.
http://www.onko-sure.com/about-onko-sure/
http://investorshub.advfn.com/boards/addPersonMrk.asp?user=205909 (CLICK IF YOU LIKE STREAMER)
We watch, We Wait & We Learn
Do Your Own due diligence
Only you can decide
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
